Clarivate Analytics announced it has signed a definitive agreement to acquire Decision Resources Group, a provider of data, analytics and insights products and services to the healthcare industry, from Piramal Enterprises Limited, part of Piramal Group. The $950M purchase price-approximately 12 times trailing DRG Adjusted EBITDA, taking into account acquisition cost synergies but not revenue synergies-includes $900M in cash and approximately $50M in Clarivate ordinary shares to be issued following the one-year anniversary of closing. The acquisition is expected to be accretive to Clarivate earnings in 2020. In 2019, DRG generated $207M of revenue, with 9% organic growth, and $47M of adjusted EBITDA before the impact of acquisition cost synergies. Clarivate expects to achieve cost synergies of approximately $30M within the first 18 months after the transaction closes, which in addition to revenue synergies, is expected to drive DRG's adjusted EBITDA growth and expand its adjusted EBITDA margin towards the 40% range. Clarivate said it remains committed to managing its balance sheet and its go-forward capital structure. The company plans to fund the transaction with a mix of debt and equity capital proceeds. In connection with the transaction, Clarivate has secured a backstop of $900M fully committed bridge facility from Citi and Goldman Sachs. Clarivate expects to obtain long-term financing with proceeds from debt and equity capital markets before the closing of the transaction. Clarivate continues to expect adjusted Revenues in a range of $950M-$970M for 2020 and adjusted EBITDA in a range of $330M-$350M.

Western Midstream Partners announced that the board of directors of its general partner declared a quarterly cash distribution of $0.622 per unit for the fourth quarter of 2019, resulting in a full-year 2019 distribution increase of 5% over the full-year 2018. This distribution represents WES's 28th consecutive quarterly distribution increase. WES's fourth quarter 2019 distribution is payable February 13, 2020, to unitholders of record at the close of business January 31, 2020.

CHS Inc. announced it has named Olivia Nelligan as its new executive vice president and chief financial officer, effective Jan. 29, 2020. Olivia Nelligan will join CHS Inc. as executive vice president and chief financial officer effective Jan. 29, 2020.

Interface announced that its Board of Directors has named Dan Hendrix, most recently Chairman of the Board of Interface as President and Chief Executive Officer, effective immediately. Hendrix will also maintain his position as Board Chairman. Hendrix succeeds Jay Gould who was terminated after an investigation concluded that he engaged in personal behavior that violated company policy and core values. Interface confirmed that this leadership transition is unrelated to the company's operational or financial performance.

Jazz Pharmaceuticals announced that the European Commission approved Sunosi to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure. Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved to treat EDS in adults living with narcolepsy or OSA and the only licensed therapy in the European Union for the treatment of EDS in adults living with OSA. Once-daily Sunosi is approved with doses of 75 mg and 150 mg for people with narcolepsy and doses of 37.5 mg, 75 mg and 150 mg for patients with OSA. At Week 12 of the Phase 3 clinical trial, 150 mg of solriamfetol for narcolepsy patients and both 75 mg and 150 mg doses for OSA patients demonstrated improvements in wakefulness compared to placebo as assessed via the maintenance of wakefulness test from approximately one hour post-dose through approximately nine hours post-dose. The European Commission approval extends to all European Union Member States, as well as Iceland, Norway and Liechtenstein. The Marketing Authorization Application for Sunosi is based on data from four randomized placebo-controlled studies included in the Treatment of Obstructive sleep apnea and Narcolepsy Excessive Sleepiness clinical trial program. Data from the studies in the TONES program demonstrated the superiority of solriamfetol relative to placebo.